Latest News

TTFields Increases Time to Progression in Patients With Brain Metastases From NSCLC
TTFields Increases Time to Progression in Patients With Brain Metastases From NSCLC

March 27th 2024

Findings from the phase 3 METIS trial found that tumor-treating fields were able to significantly improve time to intracranial progression in patients with brain metastases from non-small cell lung cancer.

Repotrectinib Elicits an Intracranial Response in ROS1+ Advanced NSCLC
Repotrectinib Elicits an Intracranial Response in ROS1+ Advanced NSCLC

March 25th 2024

Pembrolizumab/Olaparib Misses Survival End Points in NSCLC Subgroup
Pembrolizumab/Olaparib Misses Survival End Points in NSCLC Subgroup

March 21st 2024

Ongoing Data Support Frontline Triplet in NSCLC
Ongoing Data Support Frontline Triplet in NSCLC

March 16th 2024

Newer TKIs Show Better Intracranial Responses in ROS1+ NSCLC
Newer TKIs Show Better Intracranial Responses in ROS1+ NSCLC

March 13th 2024

Video Series
Video Interviews
Podcasts

More News